Tumors with HR repair deficiency (HRD) caused by loss-of-function mutations in BRCA1 or BRCA2 genes display increased sensitivity to PARP inhibition and multiple studies in HR defective prostate (5) and ovarian cancer (6) have shown activity of PARP inhibitors. This evidence concerns the gene PARP1 and ovarian carcinoma.